Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 6Unknown 2Terminated 2Not yet recruiting 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 6Rectal Neoplasms 5Colonic Neoplasms 3Stomach Neoplasms 2Pancreatic Adenocarcinoma 2Gallbladder Neoplasms 2Colorectal Neoplasms 2Bile Duct Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Intraductal Neoplasms 1Oropharyngeal Neoplasms 1Klatskin Tumor 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Borderline Resectable Pancreatic Adenocarcinoma 1Anus Neoplasms 1

Interventions

Fluorouracil 255Leucovorin 224Oxaliplatin 218Irinotecan 206Bevacizumab 200Capecitabine 144Cetuximab 136Panitumumab 68Folfox protocol 63regorafenib 50Colonoscopy 44pembrolizumab 42IFL protocol 39Radiotherapy 32Nivolumab 31Drug Therapy 27trifluridine tipiracil drug combination 26Gemcitabine 24Blood Specimen Collection 23Chemotherapy, Adjuvant 20Surveys and Questionnaires 19Celecoxib 19Surgical Procedures, Operative 16durvalumab 15Neoadjuvant Therapy 15Cyclophosphamide 14Cisplatin 14aflibercept 13Standard of Care 13Pemetrexed 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Colorectal Neoplasms × dehydroftorafur × Clear all
NCT04761614 2025-03-28

Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
13 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04164069 2024-12-27

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
9 enrolled
Gastrointestinal

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡